Three-drug combination regimen in pancreatic cancer treatment: Are we there yet?

Journal of the Pancreas

Volumn 12, Issue 2, 2011, Pages 78-82

  Kang, Soonmo Peter ^a   Saif, Muhammad Wasif ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b New York Presbyterian Hospital ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; METHOTREXATE; MITOMYCIN; OXALIPLATIN; SORAFENIB; VINCRISTINE;

BONE MARROW TOXICITY; CANCER SURVIVAL; EDITORIAL; HUMAN; LEUKOPENIA; METASTASIS; NEUTROPENIA; PANCREAS ADENOCARCINOMA; PROGRESSION FREE SURVIVAL; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; FLUOROURACIL; HUMANS; LEUCOVORIN; ORGANOPLATINUM COMPOUNDS; PANCREATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 79952785073     PISSN: 15908577     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (21)

1. T. Conroy FD, M. Ychou, M. Ducreux, O. Bouche, R. Guimbaud, Y. Becouarn, C. Montoto-Grillot, S. Gourgou-Bourgade, A. Adenis, FNCLCC-FFCD PRODIGE Group. Randomized phase III trial comparing FOLFIRINOX (F: 5FU/leucovorin [LV], irinotecan [I], and oxaliplatin [O]) versus gemcitabine (G) as firstline treatment for metastatic pancreatic adenocarcinoma (MPA): Preplanned interim analysis results of the PRODIGE 4/ACCORD 11 trial. J Clin Oncol 28:abstr 4010, 2010
2. T. Conroy BP, E. Francois, G. Deplanque, R. Bugat, J.-H. Jacob, U. Stein, S. Nasca, E. Magherini, J.-P. Metges; Ctr Alexis Vautrin, Vandoeuvre-Les Nancy, France. Final results of folfirinox: A triple combination of 5-FU/leucovorin (5-FU/LV), irinotecan (I) and oxaliplatin (O)] as first-line chemotherapy in advanced pancreatic adenocarcinoma (APA). Proc Am Soc Clin Oncol 22, 2003
3. M. Ychou FD, R. Guimbaud, M. Ducreux, O. Bouché, Y. Bécouarn, A. Adenis, C. Montoto-Grillot, E. Luporsi, T. Conroy Randomized phase II trial comparing folfirinox (5FU/leucovorin [LV], irinotecan [I] and oxaliplatin [O]) vs. gemcitabine (G) as firstline treatment for metastatic pancreatic adenocarcinoma (MPA). First results of the ACCORD 11 trial. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I 25:4516, 2007
4. Vervenne W BJ, Humblet Y, Gill S, Moore MJ, Van Laethem J, et al. A randomized, double-blind, placebo (P) controlled, multicenter phase III trial to evaluate the efficacy and safety of adding bevacizumab (B) to erlotinib (E) and gemcitabine (G) in patients (pts) with metastatic pancreatic cancer. J Clin Oncol 26:abstract 4507, 2008
5. Fine RL, Fogelman DR, Schreibman SM, et al. The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis. Cancer Chemother Pharmacol 61:167-175, 2008
6. R. L. Fine GM, W. Sherman, K. Chu, M. Maurer, J. Chabot, I. Postolov, J. Prowda, S. Schreibman, J. Levitz Phase II trial of GTX chemotherapy in metastatic pancreatic cancer. J Clin Oncol 27:abstract 4623, 2009
7. B. A. Burtness MEP, J. D. Berlin, D. K. Liles, A. E. Chapman, E. P. Mitchell, A. B. Benson Phase II ECOG trial of irinotecan/docetaxel with or without cetuximab in metastatic pancreatic cancer: Updated survival and CA19-9 results. J Clin Oncol 26:abstr 4642, 2008
8. Reni M, Passoni P, Panucci MG, et al Definitive results of a phase II trial of cisplatin, epirubicin, continuous-infusion fluorouracil, and gemcitabine in stage IV pancreatic adenocarcinoma. J Clin Oncol 19:2679-2686, 2001
9. Kozuch P, Grossbard ML, Barzdins A, et al Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer. Oncologist 6:488-495, 2001
10. Yoo C, Hwang JY, Kim JE, et al A randomised phase II study of modified FOLFIRI.3 vs. modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer. Br J Cancer 101:1658-1663, 2009
11. Sharma MR, Maitland ML, Ratain MJ Other paradigms: better treatments are identified by better trials: the value of randomized phase II studies. Cancer J 15:426-430, 2009
12. Mallinson CN, Rake MO, Cocking JB, et al Chemotherapy in pancreatic cancer: results of a controlled, prospective, randomised, multicentre trial. Br Med J 281:1589-1591, 1980
13. Palmer KR, Kerr M, Knowles G, et al Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br J Surg 81:882-885, 1994
14. H. L. Kindler KAB, H. S. Hochster, G. Friberg, K. Micetich, G. Locker, M. Kozloff, M. Moore, W. /xnamexSun/x/namex, E. E. Vokes A randomized phase II study of bevacizumab (B) and gemcitabine (G) plus cetuximab (C) or erlotinib (E) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings (Post-Meeting Edition 24:4040, 2006
15. F. Kullmann SH, M. Dollinger, J. Harder, M. Fuchs, H. Messmann, J. Trojan, E. Gaebele, A. Hinke, E. Endlicher Cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in 1st line metastatic pancreatic cancer. First results from a multicenter phase II study. 2007 Gastrointestinal Cancers Symposium General Poster Session C 2007
16. Correale P, Montagnani F, Miano S, Sciandivasci A, Pascucci A, Petrioli R, Testi W, Tanzini G, Francini G. Biweekly triple combination chemotherapy with gemcitabine, oxaliplatin, levofolinic acid and 5-fluorouracil (GOLF) is a safe and active treatment for patients with inoperable pancreatic cancer. J Chemother. 2008 Feb;20(1):119-125.
17. Garnier C RC, Chirpaz E et al Phase II study of a combination with leucovorin (LV), 5-FU bolus and infusion (FU), gemcitabine and oxaliplatin (FOLFU GEMOX regimen) in locally advanced (LA) and metastatic (M) pancreatic carcinoma (APC). Proc Am Soc Clin Oncol 20, 2001
18. Oh D LK, Lee K, Sohn C, Park Y, Zang D, et al. A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: Combined analysis with translational research. J Clin Oncol 27:abstract 4607, 2009
19. Kozuch P AM, Homel P et al. Biweekly sequential gemcitabine, 5-FU (5-fluorouracil), LV (leucovorin), and cisplatin (GFP): a highly active novel combination for metastatic adenocarcinoma of the exocrine pancreas (MPAC). Proc Am Soc Clin Oncol 20, 2001
20. Lubner SJ SW, Mulkerin D, Holen KD, Seo S, LoConte NK. Phase II study of oxaliplatin, high-dose capecitabine, and sorafenib in patients with advanced pancreatic cancer. J Clin Oncol 28:4143, 2010
21. Reni M, Panucci MG, Passoni P, et al Salvage chemotherapy with mitomycin, docetaxel, and irinotecan (MDI regimen) in metastatic pancreatic adenocarcinoma: a phase I and II trial. Cancer Invest 22:688-696, 2004